Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) - Candlesense
CRNX Regulation

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development.

Related Questions

What are the projected timelines and potential revenue milestones from development through commercialization, and how could they affect long‑term valuation? How might the FDA orphan drug designation for atumelnant influence CRNX's short‑term stock price and trading volume? What is the competitive landscape for ACTH receptor antagonists and how does atumelnant's first‑in‑class status affect CRNX's market positioning?
Find similar articles on Candlesense globenewswire